Despite barriers of blood, brain and bureaucracy, intranasal insulin may emerge as a promising treatment for pathological memory loss
The newest chemical under investigation for managing Alzheimer’s disease (AD) is actually not new at all. Insulin, the therapeutic hormone all-too familiar to individuals with diabetes, has been around for decades. In fact December will mark 90 years since its discoverers earned the Nobel Prize in Physiology or Medicine for the extraction of insulin for clinical use. Yet to say that insulin has been under our noses all these years wouldn’t exactly be correct. Because if it had been under our noses, we might have sensed its neurologic benefits sooner.
The latest insulin therapy is not delivered via injection like its diabetes-treating counterparts, nor does it come in the form of a pill or a patch like the cholinesterase inhibitors often prescribed to patients with AD. Instead this novel therapeutic enters the body through the nose—the only entry point that gives insulin a chance of reaching the brain.
A large peptide molecule, insulin from the blood cannot float easily into the brain because the blood brain barrier (BBB), a sort of neuroprotective moat, prevents its transport. Fortified by cellular guards called tight junctions, the BBB rejects many pharmacologic hopefuls, allowing entrance only to certain types of substances. Namely small or lipophilic molecules can be administered orally (or via injection, or through the skin) and as long as the relevant chemicals end up in the blood stream, they can casually saunter across the BBB and act on the brain. Large and cumbersome, insulin does not have this luxury and must therefore take a more creative route across the moat.
The nose, conspicuous and sometimes even goofy, provides that creative route. Yet it’s a route that, for many years, researchers were hesitant to take.
“They would say things like, ‘Well, why would there be a blood brain barrier if all you had to do was put something in the nose and it would go to the brain?’” says William H. Frey II, Ph.D., Research Director at HealthPartners Center for Memory & Aging. As of 1989 Frey had been “in the Alzheimer’s deal” for over a decade. At that time he was conducting clinical trials of a neurotrophic factor (a therapeutic protein) to treat AD and, because of the seeming insurmountability of the BBB, the work had been less than fruitful. “It became clear to me that, once again, this neurotrophic factor was not getting effectively into the brain,” he says. So Frey decided to sleep on it. “I went to sleep and I had a dream. And this is how I discovered the intranasal method of getting around the blood brain barrier,” he says. “It had been known since the early 1900s that a number of different viruses that got into the nose would travel up the olfactory nerves and the trigeminal nerves—both of these are nerves that go directly from the nasal mucosa right into the brain. The idea that came to me in this dream in 1989 was: if bad things can do it, why can’t good things do it?”
When Frey revisited the idea upon waking, it registered as simultaneously intuitive and absurd—a logical fantasy like so many dreams.
The Latest Bing News on:
- Intranasal Insulin Suppresses Food Intake via Enhancement of Brain Energy Levels in Humanson August 1, 2022 at 5:00 pm
In summary, our data provide evidence for a central role of brain energy metabolism in the regulation of food consumption and uncover an important function of cerebral insulin in humans.
- Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Painon August 1, 2022 at 5:35 am
Intranasal oxytocin has been shown to be well ... craniofacial pain and insulin resistance. Tonix has a license with the University of Geneva to use TNX-1900 for the treatment of insulin ...
- Intranasal Insulin Suppresses Food Intake via Enhancement of Brain Energy Levels in Humanson July 28, 2022 at 5:00 pm
Test substances were applied by intranasal spray. Each subject was administered four puffs of insulin or placebo at 60-s intervals. Each puff consisted of 0.1 mL solution containing 10 IU of ...
- Saudi Arabia Human Insulin Markets, Competition, Forecast & Opportunities, 2027on July 26, 2022 at 9:41 am
Dublin, July 26, 2022 (GLOBE NEWSWIRE) -- The "Saudi Arabia Human Insulin Market, By Indication (Type I Diabetes, Type II Diabetes), By Route of Administration (Subcutaneous, Nasal, Intravenous, ...
- Saudi Arabia Human Insulin Markets, Competition, Forecast & Opportunities, 2027on July 26, 2022 at 1:31 am
Dublin, July 26, 2022 (GLOBE NEWSWIRE) -- The "Saudi Arabia Human Insulin Market, By Indication (Type I Diabetes, Type II Diabetes), By Route of Administration (Subcutaneous, Nasal, Intravenous ...
- New Type 3 diabetes is more specific to the brainon July 24, 2022 at 9:00 pm
You've heard of Type 1 and Type 2 diabetes, but did you know there is a third type of the disease? Type 1 diabetes is something you are born with, an inability of your body to produce insulin which is ...
- Diabetes emergency: a type 1 diabetic’s insulin overdose and his first-hand account of what he did to surviveon July 20, 2022 at 1:55 am
The insulin was going to use up all the sugar in ... The tests involved three nasal swabs, two throat swabs, two armpit/groin swabs, and – a first for me – a rectal swab.
- Type 3 diabetes: Symptoms, causes and treatmentson July 14, 2022 at 9:48 am
“Because insufficient insulin signaling contributes to loss of brain cell energy in individuals with Alzheimer's disease, [I] first proposed intranasal insulin as a treatment for Alzheimer's ...
The Latest Google Headlines on:
The Latest Bing News on:
- Ohio State University: Fewer rural early-onset Alzheimer’s patients see specialistson August 6, 2022 at 1:49 am
Rural Americans suffering from early-onset Alzheimer’s are less likely than city dwellers to be seen by specialists and receive tests that can benefit both them and their families, new research has ...
- How varicella and herpes viruses may interact to trigger Alzheimer'son August 6, 2022 at 1:00 am
New research suggests that the interaction between two common viruses may be responsible for triggering the onset of Alzheimer’s disease.
- Questionable Data Jeopardizes Alzheimer’s Amyloid Theoryon August 5, 2022 at 11:00 am
Since publication, 2,300 studies have cited the UMN report. NIH’s annual funding for amyloid projects has exploded to $1.6 billion in the current fiscal year.
- Rural Americans with early-onset Alzheimer’s less likely to see a specialiston August 5, 2022 at 9:35 am
Story at a glance Ohio State University researchers found rural patients with early-onset Alzheimer’s disease, which occurs between the ages of 30 and 65, were typically seen exclusively by a primary ...
- Program will address common questions about Alzheimer's diseaseon August 5, 2022 at 9:35 am
Pam Myers: "If you are having any issues discussed during the program, it is important to follow up with your physician." ...
- Alzheimer's Researchers Delve Into Data From Failed Crenezumab Trialon August 5, 2022 at 9:32 am
In the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease ( API ADAD) trial, crenezumab failed to slow or prevent decline over 5 to 8 years in cognitively healthy Colombian ...
- Fewer rural early-onset Alzheimer's patients see specialistson August 5, 2022 at 8:00 am
Rural Americans suffering from early-onset Alzheimer's are less likely than city dwellers to be seen by specialists and receive tests that can benefit both them and their families, new research has ...
- A Diabetes Drug Could Protect Against Alzheimer’s Disease, New Research Suggestson August 5, 2022 at 6:04 am
It turns out that drugs designed to treat type 2 diabetes may be able to do a lot more than just help regulate blood glucose levels. According to new research published in the jou ...
- Study of Alzheimer's risk gene reveals potentially reversible mechanismon August 4, 2022 at 8:20 pm
MIT scientists have uncovered a mechanism for how a common genetic risk factor for Alzheimer’s contributes to the disease. It centers on lipid metabolism, and early investigations suggest it could ...
- Cold sores and shingles may be linked to Alzheimer’s, new research indicateson August 4, 2022 at 2:57 pm
Could cold sores plus shingles lead to? New research from Tufts and Oxford universities adds to the growing evidence that they might — and how. And the implication ...